Proposal from DiaGenic’s nomination committee

To the shareholders of DiaGenic ASA. Reference is made to the announcement on 1 November 2013 regarding the Extraordinary General Meeting in DiaGenic ASA to elect members to the board of directors and remuneration to the board of directors. Please find the recommendation from nomination committee  attached.

Contact:

Hanne S. Holen, Chairman

Telephone: +47 98 29 45 91

e-mail: hanne.s.holen@adeb.no

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com